Revenio Group (REG1V) Status update summary
Event summary combining transcript, slides, and related documents.
Status update summary
25 Sep, 2026Rights offering approval and structure
Finnish Financial Supervisory Authority approved the Finnish language prospectus for a fully underwritten rights offering of approximately EUR 80 million.
Subscription commitments cover about 31.4% of the offer shares, with the remainder underwritten by Nordea Bank Abp.
The subscription period runs from September 28 to October 12, 2026, with trading of subscription rights on Nasdaq Helsinki from September 28 to October 6, 2026.
Advisory and communications
Nordea acts as Global Coordinator and bookrunner, with White & Case LLP and Hannes Snellman Attorneys Ltd as legal advisors.
IR Partners Oy is the communications advisor for the offering.
Investor engagement and webcast
A live webcast in Finnish will be held on September 29, 2026, at 3:00 p.m. EEST to present the company and the offering.
A recording will be available on the company’s website after the event.
Latest events from Revenio Group
- Targeting 5%-10% sales CAGR and 25% EBITDA by 2029, driven by integration and innovation.REG1V
CMD 2026 - Q2 net sales up 48.1% as Visionix boosted growth but pressured margins and leverage.REG1V
Q2 2026 - Net sales rose 4.8% but profit dropped on Visionix costs; acquisition expands market reach.REG1V
Q1 2026 - Merger forms a top global eye care leader, targeting EUR 20m+ synergies and rapid growth.REG1V
M&A announcement - 2025 net sales up 6% to EUR 109.7M, record cash flow, and 2026 sales growth expected at 8–15%.REG1V
Q4 2025 - Q3 2025 saw strong sales and profitability, with 6–15% sales growth forecast for 2025.REG1V
Q3 2025 - Q3 net sales up 8.9%, operating profit down, AI diagnostics strengthened by Thirona Retina.REG1V
Q3 2024 - Q2 net sales up 14.2%, strong cash flow, and 2024 sales growth guidance of 5–10%.REG1V
Q2 2024 - Record Q1 sales and profit, driven by global growth and strong financials.REG1V
Q1 2025